Previous 10 | Next 10 |
2024-01-30 08:00:49 ET Kura Oncology ( NASDAQ: KURA ) shares jumped as much as 38% premarket on Tuesday after the biopharmaceutical company reported positive preliminary data from a trial evaluating its investigational drug candidate, Ziftomenib, in patients with acute myeloid l...
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of patients remain on trial as o...
2024-01-24 12:48:28 ET More on Mid-day movers $ stocks. Peraso Inc. (PRSO) Q3 2023 Earnings Call Transcript Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript Sight Sciences says Q4 total revenue i...
Kura Oncology, Inc. (NASDAQ: KURA) is one of today's top gainers. The company's shares have moved 6.27% on the day to $8.14. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of ...
2024-01-24 10:01:06 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-24 07:14:35 ET More on Kura Oncology Kura Oncology: Riding The Menin Hype Wave In AML Therapy Kura Oncology, Inc. (KURA) Q3 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q3 - Results - Earnings Call Presentation Kura Oncology GAAP EPS of -$0....
– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma cash, cash equivalents and investments expected to provide runway into 2027 – – Management to host virtual investor even...
2023-12-30 21:55:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-12 15:32:16 ET Summary Kura Oncology is an oncology-focused biotech developing targeted therapies for various forms of cancer with high unmet need. Their pipeline includes ziftomenib for AML, with promising phase 2 results and a potential data readout in 2024. They are...
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood can...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...